| eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies L Boussemart, H Malka-Mahieu, I Girault, D Allard, O Hemmingsson, ... Nature 513 (7516), 105-109, 2014 | 364 | 2014 |
| Cytochromes P450 CYP94C1 and CYP94B3 catalyze two successive oxidation steps of plant hormone jasmonoyl-isoleucine for catabolic turnover T Heitz, E Widemann, R Lugan, L Miesch, P Ullmann, L Désaubry, ... Journal of Biological Chemistry 287 (9), 6296-6306, 2012 | 265 | 2012 |
| PHB2 (prohibitin 2) promotes PINK1-PRKN/Parkin-dependent mitophagy by the PARL-PGAM5-PINK1 axis C Yan, L Gong, L Chen, M Xu, H Abou-Hamdan, M Tang, L Désaubry, ... Autophagy 16 (3), 419-434, 2020 | 243 | 2020 |
| Prohibitin ligands in cell death and survival: mode of action and therapeutic potential F Thuaud, N Ribeiro, CG Nebigil, L Désaubry Chemistry & biology 20 (3), 316-331, 2013 | 218 | 2013 |
| Translational control of tumor immune escape via the eIF4F–STAT1–PD-L1 axis in melanoma M Cerezo, R Guemiri, S Druillennec, I Girault, H Malka-Mahieu, S Shen, ... Nature medicine 24 (12), 1877-1886, 2018 | 205 | 2018 |
| Updates in anthracycline-mediated cardiotoxicity CG Nebigil, L Désaubry Frontiers in Pharmacology 9, 415242, 2018 | 181 | 2018 |
| The natural anticancer compounds rocaglamides inhibit the Raf-MEK-ERK pathway by targeting prohibitin 1 and 2 G Polier, J Neumann, F Thuaud, N Ribeiro, C Gelhaus, H Schmidt, ... Chemistry & biology 19 (9), 1093-1104, 2012 | 171 | 2012 |
| Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1 G Polier, J Ding, BV Konkimalla, D Eick, N Ribeiro, R Köhler, M Giaisi, ... Cell death & disease 2 (7), e182-e182, 2011 | 166 | 2011 |
| Cancer wars: natural products strike back C Basmadjian, Q Zhao, E Bentouhami, A Djehal, CG Nebigil, RA Johnson, ... Frontiers in chemistry 2, 20, 2014 | 156 | 2014 |
| CUG initiation and frameshifting enable production of dipeptide repeat proteins from ALS/FTD C9ORF72 transcripts R Tabet, L Schaeffer, F Freyermuth, M Jambeau, M Workman, CZ Lee, ... Nature communications 9 (1), 152, 2018 | 145 | 2018 |
| Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12 F Thuaud, Y Bernard, G Turkeri, R Dirr, G Aubert, T Cresteil, A Baguet, ... Journal of medicinal chemistry 52 (16), 5176-5187, 2009 | 112 | 2009 |
| Recent Advances in the Synthesis of C2‐Functionalized Pyridines and Quinolines Using N‐Oxide Chemistry D Wang, L Désaubry, G Li, M Huang, S Zheng Advanced Synthesis & Catalysis 363 (1), 2-39, 2021 | 108 | 2021 |
| Isozyme-dependent sensitivity of adenylyl cyclases to P-site-mediated inhibition by adenine nucleosides and nucleoside 3′-polyphosphates RA Johnson, L Désaubry, G Bianchi, I Shoshani, E Lyons, R Taussig, ... Journal of Biological Chemistry 272 (14), 8962-8966, 1997 | 106 | 1997 |
| Prokineticin‐2 promotes chemotaxis and alternative A2 reactivity of astrocytes M Neal, J Luo, DS Harischandra, R Gordon, S Sarkar, H Jin, ... Glia 66 (10), 2137-2157, 2018 | 103 | 2018 |
| Molecular pathways: the eIF4F translation initiation complex—new opportunities for cancer treatment H Malka-Mahieu, M Newman, L Désaubry, C Robert, S Vagner Clinical Cancer Research 23 (1), 21-25, 2017 | 97 | 2017 |
| Progress in copper complexes as anticancer agents R Tabti, N Tounsi, C Gaiddon, E Bentouhami, L Désaubry Med. Chem 7, 875-879, 2017 | 92 | 2017 |
| Flavaglines: potent anticancer drugs that target prohibitins and the helicase eIF4A C Basmadjian, F Thuaud, N Ribeiro, L Désaubry Future medicinal chemistry 5 (18), 2185-2197, 2013 | 79 | 2013 |
| The mTOR-S6 kinase pathway promotes stress granule assembly AP Sfakianos, LE Mellor, YF Pang, P Kritsiligkou, H Needs, ... Cell Death & Differentiation 25 (10), 1766-1780, 2018 | 75 | 2018 |
| Flavaglines as potent anticancer and cytoprotective agents N Ribeiro, F Thuaud, Y Bernard, C Gaiddon, T Cresteil, A Hild, EC Hirsch, ... Journal of medicinal chemistry 55 (22), 10064-10073, 2012 | 74 | 2012 |
| 2′, 5′-Dideoxyadenosine 3′-polyphosphates are potent inhibitors of adenylyl cyclases L Désaubry, I Shoshani, RA Johnson Journal of Biological Chemistry 271 (5), 2380-2382, 1996 | 74 | 1996 |
